Review of venom immunotherapy at a regional tertiary paediatric centre. (13th April 2022)

• Record Type: Journal Article
• Authors: Johnston, Niall; Belcher, Jan; Preece, Kahn; Bhatia, Rani
• Is Part Of: Journal of paediatrics and child health. Volume 58:Number 7(2022)
• Page Start: 1228
• Page End: 1232
• Publication Date: 2022-04-13
• Subjects: anaphylaxis -- bee venom -- immunotherapy; Children -- Health and hygiene -- Periodicals; Pediatrics -- Periodicals; 618.92
• DOI: 10.1111/jpc.15964
• Languages: English
• ISSNs: 1034-4810

Abstract

Abstract : Aim: Bee stings can result in allergic reactions, including anaphylaxis. Venom immunotherapy (VIT) is a definitive cure for bee venom allergy, but controversy surrounds whether accelerated protocols are safe in children. Our primary aim was to assess the safety profile of ultra‐rush bee VIT compared with conventional bee VIT at a regional paediatric tertiary centre. We also sought to evaluate the impact of both approaches on time and resource use. Methods: Data were collected retrospectively from 14 patients with bee venom allergy who were treated with ultra‐rush or conventional bee VIT between 2013 and 2021 at John Hunter Children's Hospital. We compared VIT‐associated adverse reactions and use of resources in both these groups. Results: Overall, six patients received ultra‐rush bee VIT and eight patients received conventional VIT. The ultra‐rush group had a lower rate of systemic reaction (16%) compared with the conventional group (25%). One patient from the conventional group required adrenaline. Ultra‐rush patients require fewer injections over a shorter time and fewer hospital visits to complete the protocol. Travel distance for families was significantly reduced. Conclusion: At our regional paediatric tertiary centre, ultra‐rush bee VIT was a safe treatment option for children with bee venom allergy. It has many advantages over a conventional approach, especially for patients living in regional or remote areas.